Alliancebernstein L.P. Cytom X Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $76,041 - $143,633	-49,700 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $534 - $936	200 Added 0.4%	49,700 $133,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $3,483 - $6,651	-900 Reduced 1.79%	49,500 $214,000
Q3 2021 Nov 10, 2021	SELL	$4.32 - $6.43 $28,944 - $43,081	-6,700 Reduced 11.73%	50,400 $257,000
Q2 2021 Jul 30, 2021	BUY	$6.33 - $9.91 $65,199 - $102,073	10,300 Added 22.01%	57,100 $361,000
Q1 2021 May 06, 2021	SELL	$6.6 - $9.0 $106,260 - $144,900	-16,100 Reduced 25.6%	46,800 $362,000
Q3 2020 Nov 12, 2020	SELL	$6.55 - $8.83 $9,825 - $13,245	-1,500 Reduced 2.33%	62,900 $418,000
Q1 2020 May 14, 2020	BUY	$3.61 - $8.6 $20,216 - $48,160	5,600 Added 9.52%	64,400 $494,000
Q4 2019 Feb 18, 2020	SELL	$5.17 - $8.91 $454,117 - $782,627	-87,837 Reduced 59.9%	58,800 $489,000
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $157,563 - $261,537	-21,350 Reduced 12.71%	146,637 $1.08 Million
Q1 2019 May 14, 2019	BUY	$9.5 - $19.16 $664,211 - $1.34 Million	69,917 Added 71.29%	167,987 $1.81 Million
Q2 2018 Aug 13, 2018	BUY	$21.38 - $29.68 $508,844 - $706,384	23,800 Added 32.05%	98,070 $2.24 Million
Q1 2018 May 14, 2018	SELL	$21.76 - $34.22 $167,987 - $264,178	-7,720 Reduced 9.42%	74,270 $2.11 Million
Q4 2017 Feb 13, 2018	BUY	$19.0 - $23.09 $157,700 - $191,647	8,300 Added 11.26%	81,990 $1.73 Million
Q3 2017 Nov 13, 2017	BUY	$13.53 - $18.17 $997,025 - $1.34 Million	73,690	73,690 $1.34 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.8M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.